Erythropoietin Drugs Market Size Worth $7.65 Billion By 2032 | CAGR: 1.3%

The global erythropoietin drugs market size is expected to reach USD 7.65 billion by 2032, according to a new study by Polaris Market Research. The report “Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anemia is a major health concern globally, and Erythropoietin Drugs are the primary treatment for the condition. According to the CDC chronic kidney disease in the United States, 15% of adults in the USA, or 37 million people are estimated to have CKD. It is more common in old age population than in people aged 45-64 years (13%) and 18-44 years (7%). Moreover, the increasing demand for biosimilars, which are cheaper alternatives to branded drugs, is expected to drive the need for Erythropoietin Drugs.

Adoption of erythropoietin drugs is greater in North America compared to other regions. This is due to several factors such as the high prevalence of anemia and chronic kidney disease, the availability of advanced healthcare infrastructure, and the presence of a large number of major pharmaceutical companies in the region.

Additionally, favorable government policies and reimbursement schemes have also contributed to the widespread adoption of erythropoietin drugs in North America. For example, in the United States, Medicare provides coverage for erythropoietin therapy for patients with end-stage renal disease, which has significantly increased access to these drugs for patients in the country.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/erythropoietin-drugs-market/request-for-sample

In February 2023, Jesduvroq tablets, manufactured by GSK, received approval from the U.S. Food and Drug Administration as the first oral treatment option for adults suffering from anaemia due to chronic kidney disease and who have undergone dialysis for at least four months. This approval represents a significant breakthrough in the treatment of anaemia caused by chronic kidney disease, as it offers a more convenient and easily accessible treatment option for patients who previously had to rely on injectable erythropoietin drugs.

In November 2022, the UK's National Health Service made a ground-breaking achievement by performing the first-ever transfusion of lab-grown RBCs grown from the donor cells. This scientific milestone could open up new avenues for treating people with the rare blood types.

Erythropoietin Drugs Market Report Highlights

• The biologics segment dominates the market, accounting for a significant share of revenue, with popular products including Procrit, NeoRecormon, Epogin, Mircera, Aranesp, and Epogen.
• The erythropoietin segment holds the largest market share in 2022. Epoetin-beta is expected to grow positively in the future due to its superiority in maintaining hemoglobin concentration in hemodialysis patients over Epoetin-alfa.
• The renal diseases segment holds the largest share of the market In 2022, due to developed reimbursement policies for renal transplants and related diseases are also driving this segment.
• North America dominated the market and is expected to grow at a highest CAGR over the projected period because of the presence of organizations advancing drug development, Medicare coverage for CKD patients, and FDA approval of drugs like Epogen, Aranesp, and Procrit.
• The global players include Amgen, Johnson & Johnson, Roche, Pfizer, Biocon, and Teva Pharmaceutical.

Polaris Market Research has segmented the Erythropoietin Drugs market report based on type, product, application and region:

Erythropoietin Drugs, Type Outlook (Revenue, USD Billion, 2019 - 2032)

• Biologics
• Biosimilars

Erythropoietin Drugs, Product Outlook (Revenue, USD Billion, 2019 - 2032)

• Erythropoietin
• Darbepoetin-alfa

Erythropoietin Drugs, Application Outlook (Revenue, USD Billion, 2019 - 2032)

• Cancer
• Renal Diseases
• Neurology
• Others

Erythropoietin Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa